Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357 · View on ClinicalTrials.gov ↗
Study Summary
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much does the amount of protein in the urine change from the start of the study to Week 36? Researchers will learn about the effect felzartamab has on the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how it is processed by the body. The study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will be randomized to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know what the participants will receive. * Participants will receive felzartamab or placebo as intravenous (IV) infusions. The treatment period will last 24 weeks. * Afterwards, participants will enter a follow-up period which will last 80 weeks. * In total, participants will have 17 study visits. Participants will stay in the study for about 2 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Felzartamab
Study Locations (20)
California
- Kidney & Hypertension Center - Apple Valley — Apple Valley
- Scripps Green Hospital — Carlsbad
- National Institute of clinical Research Administration Office — Garden Grove
- FOMAT Medical Research - FOMAT - PPDS — Oxnard
- North America Research Institute-San Dimas — San Dimas
Florida
- Nova Clinical Research, LLC — Bradenton
- Royal Research, Corp. — Hollywood
- Central Florida Kidney Specialists — Orlando
- CDC Research Institute, LLC — Port Saint Lucie
Massachusetts
- The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital — Boston
- Brigham and Women's Hospital — Boston
Michigan
- Henry Ford Hospital — Detroit
- Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS — Pontiac
Arkansas
- Applied Research Center of Arkansas — Little Rock
Georgia
- American Clinical Trials LLC — Acworth
Mississippi
- Anointed Nephrology and HTN - SKYCRNG - PPDS — Brookhaven
Missouri
- Midwest Nephrology Associates,Inc. — City of Saint Peters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2029-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06935357
The ClinicalTrials.gov registry entry for NCT06935357 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 74 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Immunoglobulin A Nephropathy (IgAN) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06935357 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06935357 about?
NCT06935357 is a clinical study titled "A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)". In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effe...
What is the current status of trial NCT06935357?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2025-05-08. Estimated completion is 2029-06-05.
What conditions does trial NCT06935357 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy (IgAN). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06935357?
The interventions under investigation include: Placebo (DRUG), Felzartamab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06935357?
This trial is sponsored by Biogen, which has 74 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06935357 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.